Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-003845
Filing Date
2025-08-25
Accepted
2025-08-25 17:20:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 14205
2 JOINT FILING AGREEMENT p25-1934exhibi99_1.htm EX-99.1 5760
  Complete submission text file 0000902664-25-003845.txt   21807
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Subject) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13G | Act: 34 | File No.: 005-84151 | Film No.: 251251941
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G